In a report released on October 28, Brandon Couillard from Jefferies maintained a Buy rating on Bio-Rad Laboratories (BIO - Research Report), with a price target of $600.00. The companys shares closed ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...

Bio-Rad Laboratories (NYSE:BIO) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement. Analysts estimate that Bio-Rad ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -6.31% in ...

Zooming in on the latest balance sheet data, we can see that Bio-Rad Laboratories had liabilities of US$613.7m due within 12 months and liabilities of US$3.15b due beyond that. Offsetting these ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Alice N. Schwartz, Bio-Rad’s co-founder and Director ...

Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...